Drug Profile

CLYM 116

Alternative Names: CLYM-116; MIL-116

Latest Information Update: 27 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Mabworks Biotech
Developer Climb Bio
Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Monoclonal antibodies
Mechanism of Action Tumour necrosis factor ligand superfamily member 13 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 May 2025 Climb Bio anticipates IND or CTA Submission in IgA nephropathy in second half of 2025
14 May 2025 Climb Bio plans a phase I trial in IgA nephropathy
09 Jan 2025 CLYM116 licensed to Climb Bio Worldwide excluding Greater China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com